DexCom (DXCM)
(Delayed Data from NSDQ)
$116.06 USD
+3.05 (2.70%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $116.06 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
DXCM 116.06 +3.05(2.70%)
Will DXCM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DXCM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DXCM
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
How to Play Intuitive Surgical (ISRG) Ahead of Q2 Earnings?
DXCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Here's Why DexCom (DXCM) is a Strong Growth Stock
Other News for DXCM
Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.
Have $50K? 7 Stocks to Buy to Retire With $1 Million by 2034
Tandem Diabetes, DexCom see weakness following ADA conference
Dexcom (DXCM) Gets a Buy from RBC Capital
Dexcom (DXCM) Gets a Buy from Jefferies